FDA fast-tracks VS-7375, an oral KRAS G12D inhibitor, opening new hope for pretreated advanced NSCLC and fueling pivotal ...
ASCO 2026 data link chronic-stress allostatic load to higher early-onset cancer risk, suggesting new tools for screening beyond genetics.